Axsome Therapeutics (AXSM) Finished Goods (2022 - 2025)
Historic Finished Goods for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $10.3 million.
- Axsome Therapeutics' Finished Goods rose 1728.24% to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year increase of 1728.24%. This contributed to the annual value of $9.0 million for FY2024, which is 681.32% down from last year.
- Axsome Therapeutics' Finished Goods amounted to $10.3 million in Q3 2025, which was up 1728.24% from $9.5 million recorded in Q2 2025.
- Axsome Therapeutics' 5-year Finished Goods high stood at $10.3 million for Q3 2025, and its period low was $1.6 million during Q4 2022.
- In the last 4 years, Axsome Therapeutics' Finished Goods had a median value of $8.8 million in 2024 and averaged $7.9 million.
- As far as peak fluctuations go, Axsome Therapeutics' Finished Goods surged by 50647.8% in 2023, and later crashed by 1199.92% in 2025.
- Quarter analysis of 4 years shows Axsome Therapeutics' Finished Goods stood at $1.6 million in 2022, then soared by 506.48% to $9.6 million in 2023, then fell by 6.81% to $9.0 million in 2024, then increased by 15.17% to $10.3 million in 2025.
- Its Finished Goods was $10.3 million in Q3 2025, compared to $9.5 million in Q2 2025 and $9.0 million in Q1 2025.